Replimune Group REPL
Nasdaq · Biological Products, (No Diagnostic Substances)$19.23−2.93%Nov 19 close · Databento
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
On the Wire
what REPL did at the next close after each storyJul 30
Replimune's RP1 wins 10-3 FDA advisory committee vote for advanced melanoma
—GlobeNewswire · 6:15 PM ET
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.